Lipids & metabolic liver disease
American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia
Methodological detailsGRADE framework, based on systematic reviews of RCTs or cohort studies
- GRADE framework
- Based on systematic reviews of RCTs or cohort studies
Recommendations
As issued by the authors
- good practice statement
Assess the risk of atherosclerotic cardiovascular disease (ASCVD) events for primary prevention in adults with dyslipidemia
- suggested
Alirocumab, evolocumab or bempedoic acid for adults with ASCVD or at increased ASCVD risk, in addition to standard care
- suggested against
Alirocumab, evolocumab or bempedoic acid in adults without ASCVD
- insufficient evidence
For or against the addition of inclisiran
- suggested
Eicosapentaenoic acid (but not eicosapentaenoic acid plus docosahexaenoic acid) for adults with hypertriglyceridemia and ASCVD or increased ASCVD risk
- strongly recommended against
Niacin for adults with hypertriglyceridemia and ASCVD or increased ASCVD risk
- insufficient evidence
Pharmacologic management in adults with severe hypertriglyceridemia (≥500 mg/dL)
- suggested
LDL-C treatment goal of <70 mg/dL in adults with dyslipidemia and ASCVD or at increased ASCVD risk
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →